Literature DB >> 15805152

High frequency of APOB gene mutations causing familial hypobetalipoproteinaemia in patients of Dutch and Spanish descent.

S W Fouchier1, R R Sankatsing, J Peter, S Castillo, M Pocovi, R Alonso, J J P Kastelein, J C Defesche.   

Abstract

BACKGROUND: Familial hypobetalipoproteinaemia (FHBL) is an autosomal co-dominant hereditary disorder of lipoprotein metabolism characterised by decreased low density lipoprotein (LDL) cholesterol and apolipoprotein B (APOB) plasma levels. High levels of plasma APOB and LDL cholesterol are strong predictors for risk of cardiovascular disease (CVD), while individuals with low APOB and LDL cholesterol levels are thought to have lower than average risk for CVD, and in fact, heterozygous FHBL patients appear to be asymptomatic.
METHODS: Rather than identifying truncated APOB proteins in plasma fractions separated by gel electrophoresis, which will miss any mutations in proteins smaller than 30 kb, we analysed the APOB gene directly, using PCR.
RESULTS: We identified nine different mutations, six of which are novel. Each mutation showed complete co-segregation with the FHBL phenotype in the families, and statistically significant differences between carriers and non-carriers were found for plasma total, LDL, and HDL cholesterol, triglycerides, and APOB levels, but not for APOA1 levels. All carriers of an APOB mutation were completely free from CVD.
CONCLUSIONS: Prolonged low levels of LDL cholesterol and elevated levels of HDL cholesterol may reduce the progression of atherosclerotic disease, but this has not been unequivocally shown that this is indeed the case in individuals with FHBL, and is the subject of a current study.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15805152      PMCID: PMC1736043          DOI: 10.1136/jmg.2004.029454

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  6 in total

1.  Hepatic steatosis does not cause insulin resistance in people with familial hypobetalipoproteinaemia.

Authors:  M E Visser; N M Lammers; A J Nederveen; M van der Graaf; A Heerschap; M T Ackermans; H P Sauerwein; E S Stroes; M J Serlie
Journal:  Diabetologia       Date:  2011-05-06       Impact factor: 10.122

2.  Recent progress in understanding protein and lipid factors affecting hepatic VLDL assembly and secretion.

Authors:  Meenakshi Sundaram; Zemin Yao
Journal:  Nutr Metab (Lond)       Date:  2010-04-27       Impact factor: 4.169

3.  Rare and common variants of APOB and PCSK9 in Korean patients with extremely low low-density lipoprotein-cholesterol levels.

Authors:  Chan Joo Lee; Yunbeom Lee; Sungha Park; Seok-Min Kang; Yangsoo Jang; Ji Hyun Lee; Sang-Hak Lee
Journal:  PLoS One       Date:  2017-10-16       Impact factor: 3.240

4.  Impaired Cytoskeletal and Membrane Biophysical Properties of Acanthocytes in Hypobetalipoproteinemia - A Case Study.

Authors:  Anne-Sophie Cloos; Laura G M Daenen; Mauriane Maja; Amaury Stommen; Juliette Vanderroost; Patrick Van Der Smissen; Minke Rab; Jan Westerink; Eric Mignolet; Yvan Larondelle; Romano Terrasi; Giulio G Muccioli; Andra C Dumitru; David Alsteens; Richard van Wijk; Donatienne Tyteca
Journal:  Front Physiol       Date:  2021-02-23       Impact factor: 4.566

5.  Gene network analysis to determine the effect of hypoxia-associated genes on brain damages and tumorigenesis using an avian model.

Authors:  Hamed Kharrati-Koopaee; Esmaeil Ebrahimie; Mohammad Dadpasand; Ali Niazi; Rugang Tian; Ali Esmailizadeh
Journal:  J Genet Eng Biotechnol       Date:  2021-07-08

Review 6.  Unmet Needs in LDL-C Lowering: When Statins Won't Do!

Authors:  Stephan Krähenbühl; Ivana Pavik-Mezzour; Arnold von Eckardstein
Journal:  Drugs       Date:  2016-08       Impact factor: 9.546

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.